Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association

Dec 2, 2024Diabetes care

Combined GLP-1 and Dual GIP/GLP-1 Receptor Agonists: American Diabetes Association Guidance

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Temporary shortages of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have increased the marketing of compounded formulations.

The use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists has significantly risen for type 2 diabetes and obesity treatment.
Shortages of these medications have raised concerns about the safety and efficacy of compounded formulations that bypass regulatory standards.
Even with improving availability of standard medications, compounded products remain widely advertised to individuals with diabetes and obesity.
Guidance is necessary for healthcare professionals and patients to ensure safety and optimal care amidst these medication challenges.

AI simplified

The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity. Increased demand for these pharmacotherapies has resulted in temporary product shortages for both GLP-1 RA and dual GIP/GLP-1 RA medications. These shortages, in part, have led to entities producing and marketing compounded formulations that bypass regulatory measures, raising safety, quality, and efficacy concerns. Even as shortages resolve, compounded GLP-1 RA and GIP/GLP-1 RA products continue to be heavily marketed to people with diabetes and obesity. The purpose of this statement by the American Diabetes Association is to guide health care professionals and people with diabetes and/or obesity in these circumstances of medication unavailability to promote optimal care and medication use safety.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief